Multicenter characterization and validation of the intron-8 poly(T) tract (IVS8-T) status in 25 Coriell cell repository cystic fibrosis reference cell lines for cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation assays.

Cystic fibrosis (CF) is the most common life-limiting recessive genetic disorder in Caucasians, with a carrier frequency of ∼1 in 25 and incidence of ∼1 in 2500–3300 live births (1). CF is caused by mutations affecting the transmembrane conductance regulator (CFTR) gene localized on the long arm of chromosome 7 (7q31.2). CFTR contains 27 exons and encodes a protein of 1480 amino acids that functions as a cAMP-regulated chloride channel in the apical membrane of epithelial cells (2)(3). Mutations in the CFTR gene lead to dysfunction of the lungs, sweat glands, testes, ovaries, intestines, and pancreas. More than 1000 mutations in this gene have been identified to date (4). The clinical manifestations of the disease are variable, ranging from severe pulmonary disease with pancreatic insufficiency to mild pulmonary disease and pancreatic sufficiency (1). Moreover, mutations in the CFTR gene have also been found in patients who have normal lung function but show other clinical signs, such as congenital bilateral absence of the vas deferens (CBAVD), nasal polyposis, bronchiectasis, and bronchopulmonary allergic aspergillosis (5)(6). Some of the variability in the CF phenotype has been attributed to the influence of the 5T allele at a polymorphic poly(T) tract in intron 8 (IVS8-T) of the CFTR gene. Genotype–phenotype correlations have shown that there is a strong association of the 5T allele with male infertility caused by congenital CBAVD and with other monosymptomatic forms of CF, such as bronchiectasis and chronic idiopathic pancreatitis (5)(6 …

[1]  A. Mirmohammadsadegh,et al.  Molecular cloning and characterization of alternatively spliced mRNA isoforms from psoriatic skin encoding a novel member of the S100 family , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  N. Udvarhelyi,et al.  Heterogenous S-100B Protein Expression Patterns in Malignant Melanoma and Association with Serum Protein Levels , 2003, Oncology.

[3]  C. Heizmann,et al.  Differential expression of S100 proteins in the developing human hippocampus and temporal cortex , 2003, Microscopy research and technique.

[4]  C. Garbe,et al.  Diagnostic value and prognostic significance of protein S‐100β, melanoma‐inhibitory activity, and tyrosinase/MART‐1 reverse transcription‐polymerase chain reaction in the follow‐up of high‐risk melanoma patients , 2003, Cancer.

[5]  V. Vives,et al.  Visualization of S100B‐positive neurons and glia in the central nervous system of EGFP transgenic mice , 2003, The Journal of comparative neurology.

[6]  W. Grody,et al.  Cystic fibrosis carrier screening: Issues in implementation , 2002, Genetics in Medicine.

[7]  W. Grody,et al.  Standards and Guidelines for CFTR Mutation Testing , 2002, Genetics in Medicine.

[8]  C. Heizmann,et al.  S100 proteins: structure, functions and pathology. , 2002, Frontiers in bioscience : a journal and virtual library.

[9]  A. Schmidt,et al.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. , 2001, The Journal of clinical investigation.

[10]  J. Goldblatt,et al.  Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. , 2001, The European respiratory journal.

[11]  K. Klinger,et al.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening , 2001, Genetics in Medicine.

[12]  H. Huttunen,et al.  Coregulation of Neurite Outgrowth and Cell Survival by Amphoterin and S100 Proteins through Receptor for Advanced Glycation End Products (RAGE) Activation* , 2000, The Journal of Biological Chemistry.

[13]  Schafer,et al.  Erratum to: differential expression of S100B(1) and S100A6(1) in the human fetal and aged cerebral cortex. , 2000, Brain research. Developmental brain research.

[14]  K. Haglid,et al.  A New Specific Method for Measuring S-100B in Serum , 2000, The International journal of biological markers.

[15]  E. Buratti,et al.  Functional analysis of cis-acting elements regulating the alternative splicing of human CFTR exon 9. , 1999, Human molecular genetics.

[16]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[17]  Brenner,et al.  Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy , 1999, The British journal of dermatology.

[18]  M. Goossens,et al.  Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. , 1998, The Journal of clinical investigation.

[19]  E. Trabetti,et al.  CFTR gene variant IVS8-5T in disseminated bronchiectasis. , 1996, American journal of human genetics.

[20]  M Claustres,et al.  Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. , 1995, The New England journal of medicine.

[21]  L. Tsui,et al.  A mutation in CFTR produces different phenotypes depending on chromosomal background , 1993, Nature Genetics.

[22]  Ronald G. Crystal,et al.  Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA , 1993, Nature Genetics.

[23]  L. Tsui,et al.  Erratum: Identification of the Cystic Fibrosis Gene: Genetic Analysis , 1989, Science.

[24]  J. Riordan,et al.  Identification of the Cystic Fibrosis Gene : Chromosome Walking and Jumping Author ( s ) : , 2008 .

[25]  B. Kerem,et al.  The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. , 1997, American journal of human genetics.